Target intelligence / Profile preview

Structure-specific endonuclease subunit MUS81 (MUS81)

Target
MUS81
Molecular classification
Enzyme, Structure-specific endonuclease
01

Overview

Structure-specific endonuclease subunit MUS81 (MUS81) is a highly conserved nuclear enzyme that functions as part of a heterodimeric endonuclease complex (MUS81–EME1/EME2 in humans). This complex specifically cleaves branched DNA structures that arise during DNA replication and recombination, such as stalled replication forks and Holliday junctions, to facilitate the repair of DNA damage and resolution of recombination intermediates. MUS81's activity is critical during S phase and G2/M of the cell cycle, particularly in response to DNA damage and replication stress. The loss of MUS81 function results in hypersensitivity to DNA crosslinking agents and defects in chromosome segregation, highlighting its pivotal role in maintaining genome stability and preventing malignancy.

Other names
MUS81FLJ44872SLX3Crossover junction endonuclease MUS81MUS81 endonuclease homologSLX3 structure-specific endonuclease subunit homolog (S. cerevisiae)
02

Mechanism of action

Not directly drug-targeted; the enzymatic action is a structure-specific endonuclease cleaving branched DNA during homologous recombination repair and replication stress.

03

Biological functions

DNA repair (homologous recombination)Resolution of DNA replication intermediatesProcessing of Holliday junctions and branched DNAMaintenance of genome stability
04

Disease associations

CancerGenome instability disordersHypersensitivity to chemotherapeutic DNA crosslinkers
05

Safety considerations

Targeting MUS81 or its pathway could induce genomic instabilityLoss-of-function causes cell hypersensitivity to DNA damage and defects in DNA repair, leading to increased mutation rates and potential secondary malignancy risk
06

Interacting drugs

No approved or investigational drugs directly target MUS81 as of now
07

Biomarkers

Increased sensitivity to DNA-crosslinking agents (such as mitomycin C, cisplatin) in models with MUS81 deficiencyNo established clinical biomarkers

Beyond the preview

Go deeper on Structure-specific endonuclease subunit MUS81 (MUS81).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Structure-specific endonuclease subunit MUS81 (MUS81).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call